Browse drugs

…ted the true neuroprotective effects of GLP-1 RAs compared with metformin. This underscores the potential superiority of GLP-1 RAs and hi…

…CI −0.53 to 0.86 events per 1000 person-years) or compared with DPP-4is (HR 0.94; 95% CI 0.71 to 1.24, rate difference −0.18; 95% CI −0…

…g reports of suicidal ideation and behaviors in patients taking GLP-1 RAs. This study assessed a potential association with intentional s…

…Objective Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly recognised for benefits beyond glycaemic cont…

…ficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in children and adolescents with obesity, overweight, pre-diab…

…intensification or change was 1.6 (0.7) and 1.4 (0.7) years for semaglutide and alternative treatment, with no subgroup differences noted (…

…) is an alternative. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been associated with reduced headache burden and visual s…

…entias (non-VaDs) (AHR 0.75; 95% CI 0.70 to 0.81) compared with metformin. No significant difference was observed for VaD. Subgroup analy…

…horts: those prescribed GLP-1 RAs (dulaglutide, semaglutide, or tirzepatide) and a control group with no exposure to GLP-1-based therapies.…

…s demonstrated that demographic factors, BMI, type of GLP-1 RA (Tirzepatide, Semaglutide and Liraglutide), indication and the presence of d…

…e clinical outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective metabolic therapies with potential anti-inflamma…

…The emergence of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual gut hormone therapies has revolutionised obesity trea…